The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Pictured: 3D illustration of a tumor on a mind/iStock, wildpixel
Kazia Therapeutics on Wednesday unveiled extra information from the Section II/III GBM-AGILE examine, choosing out...